Board of Directors

John McDonough

Chairman of the Board

Mr. McDonough previously served as President and chief executive officer, of T2 BioSystems, Inc., a diagnostics company focused on the rapid detection of sepsis-causing pathogens. Mr. McDonough held several positions at Cytyc Corporation, a company focused on women’s health, and ultimately served as president of Cytyc Development Corporation. He also led the efforts that resulted in Cytyc’s acquisition by Hologic Inc. for over $6 billion. Mr. McDonough is currently a member of the board of directors at Solace Therapeutics and Cytrellis Biosystems. He earned his undergraduate degree in business from Stonehill College.

Other directorships: Cytrellis Biosystems, Inc. (Chair), Solace Therapeutics

Don Hardison

Vice Chairman of the Board

Mr. Hardison most recently served as President, Chief Executive Officer, and as a member of the board of directors of Biotheranostics, Inc., an oncology-focused molecular diagnostics company which was acquired by Hologic Inc. Prior to Biotheranostics, he was the President and Chief Executive Officer and Director of Good Start Genetics, a molecular diagnostics company focused on reproductive health. Earlier in his career, he held many executive and senior management positions at a number of public companies including Laboratory Corporation of America and Quest Diagnostics, the two largest US clinical laboratories; Exact Sciences Corporation, a molecular diagnostics company; and SmithKline Beecham Corporation, a pharmaceutical company. He received his Bachelor of Arts in Political Science from the University of North Carolina, Chapel Hill.

Other directorships: HTG MOLECULAR, MDXHEALTH, Cytek Biosciences, Arima Genomics, YourBio, Genoescopy, Breath BioMedical

Michael S. Singer

Board Member

Dr. Singer is currently Chairman and Chief Scientific Strategy Officer (CSO) and co-founder of Cartesian Therapeutics, Inc, a US biotech company that develops RNA-modified cell therapies. Prior to founding Cartesian, he was co-founder and CSO Chief Scientific Officer of two startups: Topokine Therapeutics and HealthHonors. Dr. Singer previously served as Director of Translational Medicine at the Novartis Institutes for Biomedical Research. He is a licensed physician and has been admitted to practice patent law. He serves as an adjunct professor at the Yale University School of Medicine. Dr. Singer completed residency at Harvard and holds a BS, MD, and PhD from Yale University.

Other directorships: Cartesian Therapeutics, Pykus Therapeutics, Anodyne Nanotech

Ninfa M. Saunders

Board Member

Ms. Saunders has over 30 years of healthcare experience from the bedside as a clinical nurse specialist to C-suite roles, topping off her career as president and CEO of multi-hospital systems. As a healthcare executive, she maintained a laser focus on strategy, operations and people while optimizing patient care and enhancing the bottom line. She created innovative strategies that accelerated growth, strengthened operations, and saved lives. As CEO of Navicent Health, Ms. Saunders expanded the hospital’s reach in Georgia through mergers and acquisitions, partnerships, new service lines, and a strategic alliance with 30+ hospitals region-wide. In 2019, she orchestrated a merger with Charlotte-based Atrium Health to position Navicent for future growth and sustainability.

Other directorships: Quorum Health, T2 Biosystems, Medical Brain, Avia, Laudio, United States Health of Care, CVS/Aetna, Wesleyan College, Jefferson Health

Henrik Juuel

Board Member

Henrik Juuel has been EVP & CFO for Bavarian Nordic A/S since 2018. Prior to Bavarian Nordic, he served as CFO for Orexo AB, a Swedish specialty pharmaceutical company listed on the Nasdaq Stockholm exchange and prior to that held senior positions at various companies including CFO of GN ReSound, CFO of Virgin Mobile (Central and Eastern Europe) and CFO of NNE Pharmaplan. He began his career at Novo Nordisk in 1992 and during his 15-year tenure with the company held several senior finance positions in Denmark and abroad. He holds an MSc in Economics and Business Administration from University of Aarhus (DK) and University of Leuven (B).

Mats Thorén

Board Member

Mats Thorén brings 25 years of financial market experience, specializing in healthcare through roles in equity analysis and corporate finance. He has spent 19 years as a Healthcare investment expert, working with firms like Nalka Life Science AB and MedCap AB, and now leads Vixco Capital. Mats holds board positions at FluoGuide A/S, Xbrane BioPharma AB, Arcoma AB, and Herantis Pharma Oy, with past board roles at C-Rad AB, Cellartis AB, and others. His educational background includes Economics, focusing on Accounting and Financial Economics, and medical studies at the Karolinska Institute in Stockholm.

Mats Thorén is considered independent according to the Danish Corporate Governance.